August 23, 2018 — The U.S. Food and Drug Administration today approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I and II hereditary angioedema (HAE). HAE is a rare…Original Article
FDA Approves Takhzyro (lanadelumab-flyo) for Hereditary Angioedema
